83 assets in Biliary Tract Cancer

Therapeutic assets addressing Biliary Tract Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Abbv-400 Biliary Tract Cancer	AbbVie	P1	CC (43)
azd4360 Biliary Tract Cancer	AstraZeneca	P1/2	CC (43)
bnt141 Biliary Tract Cancer	BioNTech SE	P1/2	CC (43)
hx009 Biliary Tract Cancer	Hangzhou Hanx Biopharmaceuticals, Ltd.	P1/2	CC (43)
ide892 Biliary Tract Cancer	IDEAYA Biosciences	P1	CC (43)
Ifebemtinib Biliary Tract Cancer	Hangzhou Hanx Biopharmaceuticals, Ltd.	P1/2	CC (43)
Itraconazole Biliary Tract Cancer	AbbVie	P1	CC (43)
MAT2A-IN-9 Biliary Tract Cancer	IDEAYA Biosciences	P1	CC (43)
mdx2001 Biliary Tract Cancer	ModeX Therapeutics, An OPKO Health Company	P1/2	CC (43)
mt-4561 Biliary Tract Cancer	Tanabe Pharma America, Inc.	P1/2	CC (43)
Sacituzumab Tirumotecan Biliary Tract Cancer	Merck Sharp & Dohme LLC	P1/2	CC (43)
st-01156 Biliary Tract Cancer	SEED Therapeutics, Inc.	P1	CC (43)
tj033721 Biliary Tract Cancer	I-Mab Biopharma US Limited	P1	CC (43)
tu2218 Biliary Tract Cancer	TiumBio Co., Ltd.	P1/2	CC (43)
xh001 Biliary Tract Cancer	Shenzhen Xinhe Biomedical	P1	CC (43)
xnw27011 Biliary Tract Cancer	Evopoint Biosciences Inc.	P1/2	CC (43)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer Biliary Tract Cancer	Taiho Pharmaceutical Co., Ltd.	P1	CC (42)
Anti-Ex02 Car T Cells Biliary Tract Cancer	Zhang Xiaofeng,MD	Early P1	C (39)
Bl-M05D1 Biliary Tract Cancer	SystImmune Inc.	P1	C (39)
Bl-M07D1 Biliary Tract Cancer	SystImmune Inc.	P1	C (39)
ff-10832 gemcitabine liposome Biliary Tract Cancer	Fujifilm Pharmaceuticals U.S.A., Inc.	P1	C (39)
Futibatinib Biliary Tract Cancer	Taiho Pharmaceutical Co., Ltd.	P1	C (39)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tigit (T-Cell Immunoreceptor With Ig Domain And Itim, V-Set Ig Member 9, Vsig9, V-Set And Transmembrane Member 3, Vstm3)], Humanized Monoclonal Antibody; Gamma1 Heavy Chain Humanized (1-448) [Vh (Homo Sapiens Ighv3-4801 (90.8%) -(Ighd) -Ighj401 (92.3%)) Cdr-Imgt [8.8.12] (26-33.51-58.97-108) (1-119) -Homo Sapiens Ighg101, G1M17,1, G1V14 Ch2 A1.3, A1.2 (Ch1 K120 (216) (120-217), Hinge 1-15 (218-232), Ch2 L1.3>A (236), L1.2>A (237) (233-342), Ch3 D12 (358), L14 (360) (343-447), Chs K>Del (448)) (120-448)], (222-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-1601 (89.5%) -Igkj401 (100%)) Cdr-Imgt [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo Sapiens Igkc01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In A Chinese Hamster Ovary (Cho)-K1 Cell Line, Glycoform Alfa Biliary Tract Cancer	Taiho Pharmaceutical Co., Ltd.	P1	C (39)
Lncb74 Biliary Tract Cancer	NextCure, Inc.	P1	C (39)
Pimitespib Biliary Tract Cancer	Taiho Pharmaceutical Co., Ltd.	P1	C (39)
Tas-102 Biliary Tract Cancer	Taiho Pharmaceutical Co., Ltd.	P1	C (39)
Tas-115 Biliary Tract Cancer	Taiho Pharmaceutical Co., Ltd.	P1	C (39)
Teonanacatl Biliary Tract Cancer	University of Nebraska	P1	C (39)
Zimberelimab Biliary Tract Cancer	Taiho Pharmaceutical Co., Ltd.	P1	C (39)
zm008 Biliary Tract Cancer	Zumutor Biologics Inc.	P1	C (39)
cdh17 car-t Biliary Tract Cancer	Zhejiang University	Early P1	C (36)
Fast Laco-Stim Cdh17 Car-T Biliary Tract Cancer	Zhejiang University	Early P1	C (36)
Tripegfilgrastim Biliary Tract Cancer	National Cancer Center, Korea	P2	NR ()

Showing 51 to 83 of 83 assets

PreviousPage 2 of 2Next